Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
Giovanni Caocci, Giorgio La Nasa
Topics & Concepts
ARDSMedicineCoronavirus disease 2019 (COVID-19)RuxolitinibAcute respiratory distressInternal medicineHematologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakIntensive care medicineRespiratory distressEmergency medicineVirologyLungSurgeryInfectious disease (medical specialty)DiseaseBone marrowOutbreakMyelofibrosisCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19Sepsis Diagnosis and Treatment